Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Salvador Martín Algarra
Based on 5 articles published since 2008
||||

Between 2008 and 2019, S. M. Algarra wrote the following 5 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline SEOM clinical guideline for the management of malignant melanoma (2017). 2018

Berrocal, A / Arance, A / Castellon, V E / de la Cruz, L / Espinosa, E / Cao, M G / Larriba, J L G / Márquez-Rodas, I / Soria, A / Algarra, S M. ·Servicio de Oncología Médica, Consorcio Hospital General Universitario de Valencia, Avda. Tres Cruces 2, 46014, Valencia, Spain. berrocal.alf@gmail.com. · Hospital Clinic I Provincial de Barcelona, Barcelona, Spain. · Hospital Torrecárdenas, Almería, Spain. · Complejo Hospitalario Regional Virgen Macaren, Seville, Spain. · Hospital Universitario la Paz, Madrid, Spain. · Hospital Universitario Quirón Dexeus, Barcelona, Spain. · Hospital Universitario Clínico San Carlos, Madrid, Spain. · Hospital General Universitario Gregorio Marañón, Madrid, Spain. · Hospital Universitario Ramón y Cajal, Madrid, Spain. · Clínica Universitaria de Navarra, Pamplona, Spain. ·Clin Transl Oncol · Pubmed #29116432.

ABSTRACT: All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.

2 Review Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. 2013

Ascierto, Paolo A / Gogas, Helen J / Grob, Jean Jacques / Algarra, Salvador Martín / Mohr, Peter / Hansson, Johan / Hauschild, Axel. ·Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G. Pascale," Naples, Italy. paolo.ascierto@gmail.com ·Crit Rev Oncol Hematol · Pubmed #22874771.

ABSTRACT: Interferon alfa (IFNα) and pegylated IFNα2b (PegIFNα2b) are the only agents currently approved for the adjuvant treatment of resected melanoma at high risk of recurrence. Meta-analyses showed statistically significant disease-free survival (DFS) and overall survival (OS) benefits versus controls but did not clarify optimal dose/duration. We review data from all recent clinical trials to provide the latest information on dose, duration, and potential predictive factors of treatment success. Recent data largely confirm DFS and OS benefits but optimal dose/duration is not clarified. The data suggest greater responses in patients with stage III micro-metastatic versus macro-metastatic disease, and ulceration may also predict greater sensitivity to therapy, although further investigation is needed. Presently, IFNα and PegIFNα2b remain valid adjuvant therapies following resection of high-risk melanoma; the most appropriate treatment regimen should be determined on an individual patient basis according to patient lifestyle and approach, potential for toxicity, and the available clinical evidence.

3 Review Immunotherapy of distant metastatic disease. 2009

Schadendorf, D / Algarra, S M / Bastholt, L / Cinat, G / Dreno, B / Eggermont, A M M / Espinosa, E / Guo, J / Hauschild, A / Petrella, T / Schachter, J / Hersey, P. ·Department of Dermatology, University Hospital Essen, Essen, Germany. dirk.schadendorf@uk-essen.de ·Ann Oncol · Pubmed #19617297.

ABSTRACT: Immunotherapy of metastatic melanoma consists of various approaches leading to specific or non-specific immunomodulation. The use of FDA-approved interleukin (IL)-2 alone, in combination with interferon alpha, and/or with various chemotherapeutic agents (biochemotherapy) is associated with significant toxicity and poor efficacy that does not improve overall survival of 96% of patients. Many studies with allogeneic and autologous vaccines have demonstrated no clinical benefit, and some randomised trials even showed a detrimental effect in the vaccine arm. The ongoing effort to develop melanoma vaccines based on dendritic cells and peptides is driven by advances in understanding antigen presentation and processing, and by new techniques of vaccine preparation, stabilisation and delivery. Several agents that have shown promising activity in metastatic melanoma including IL-21 and monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) or CD137 are discussed. Recent advances of intratumour gene transfer technologies and adoptive immunotherapy, which represents a promising although technically challenging direction, are also discussed.

4 Article SEOM guidelines for the management of Malignant Melanoma 2015. 2015

Berrocal, A / Arance, A / Espinosa, E / Castaño, A G / Cao, M G / Larriba, J L G / Martín, J A L / Márquez, I / Soria, A / Algarra, S M. ·Servicio de Oncología Médica, Consorcio Hospital General Universitario de Valencia, Avda. Tres Cruces 2, 46014, Valencia, Spain. berrocal.alf@gmail.com. · Hospital Clinic I Provincial de Barcelona, Barcelona, Spain. · Hospital Universitario la Paz, Madrid, Spain. · Hospital Universitario Marqués de Valdecilla, Santander, Spain. · Hospital Universitario Quirón Dexeus, Barcelona, Spain. · Hospital Universitario Clínico San Carlos, Madrid, Spain. · Hospital Universitario 12 de Octubre, Madrid, Spain. · Hospital General Universitario Gregorio Marañón, Madrid, Spain. · Hospital Universitario Ramón y Cajal, Madrid, Spain. · Clínica Universitaria de Navarra, Pamplona, Spain. ·Clin Transl Oncol · Pubmed #26669314.

ABSTRACT: All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.

5 Article Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries. 2015

Wainstein, Alberto / Algarra, Salvador Martin / Bastholt, Lars / Cinat, Gabriela / Demidov, Lev / Grob, Jean Jacques / Guo, Jun / Hersey, Peter / Espinosa, Enrique / Schachter, Jacob / Whitaker, Dagmar / Quirt, Ian / Hauschild, Axel / Rutkowski, Piotr. ·1Faculdade de Ciências Médicas, Minas Gerais, Brazil; 2Clinica Universitaria de Navarra, Pamplona, Spain; 3Odense University Hospital, Odense, Denmark; 4Instituto de Oncologia Angel Rolfo, Buenos Aires, Argentina; 5Blokhin Cancer Center, Moscow, Russia; 6Hospital Sainte Marguerite, Marseilles, France; 7Beijing Cancer Hospital, Beijing, China; 8Newcastle University, Newcastle, Australia; 9Hospital La Paz, Madrid, Spain; 10Sheba Medical Center, Tel Hashomer, Israel; 11Melanoma Advisory Board South Africa, Cape Town, South Africa; 12Princess Margaret Hospital, Toronto, Canada; 13University of Kiel, Kiel, Germany; 14M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. ·Am J Ther · Pubmed #24914500.

ABSTRACT: Risk factors for melanoma are well known and have guided plans for primary and secondary prevention. The presentation of the disease, however, varies widely depending on the geographic area, ethnicity, and socioeconomic status. For this reason, many countries have developed specific strategies to increase public awareness and favor early diagnosis. Awareness campaigns, doctor education, and screening of high-risk subjects have all contributed to improve disease outcome in developed countries. The role of primary care physicians is particularly relevant in this regard. Developing countries are trying to implement similar measures. Future efforts to further improve the efficacy of preventive strategies should focus on populations that usually escape campaigns, such as elderly men and people with low socioeconomic status. Fast-growing tumors also require specific attention.